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Abstract
Background: Frailty is a state of physiological vulnerability common in the elderly. It is more predominant in patients
with Chronic Kidney Disease in comparison to healthy subjects, which can also be diagnosed in non-elderly individuals
and be associated with innumerous causes such as muscle strength, body composition and inflammation. The
association between frailty and endothelial function, as well as the association between frailty and the combined
outcome of mortality multiple cause and start of renal replace therapy were assessed.
Methods: In the initial analysis, sixty-one predialysis patients with Chronic Kidney Disease stages were evaluated and
included in this study. Due to patient drop-out during follow-up, fifty-seven patients were subsequently re-evaluated
12 months later. The diagnosis of frailty was based on the Johansen et al. (J Am Soc Nephrol 18(11):2960-67, 2007)
criteria. The groups were divided into Non-frail and Frail. Sociodemographic, inflammatory markers (IL-6, TNF-?, CRP-us),
endothelial dysfunction (flow-mediated vasodilatation - FMD), body composition (DXA) and the 25-hidroxi-vitamin D
parameters were analyzed.
Results: The average age of the patients used in the study was 64.9 ± 10.3 years old. The predominance of frailty was
42.6 %, of which 46 % were non-elderly. After some adjustments, frailty was associated with gender (OR = 11.32; IC
95 % = 2.30 to 55.67), advanced age (OR = 4.07; IC 95 % = 1.02 to 16.20), obesity (OR = 6.63; IC 95 % = 0.82 to 11.44)
and endothelial dysfunction (OR = 3.86; IC 95 % = 1.00 to 14.88). The ratio of the incidence of frail subjects to the
variable outcome was 2.5 (CI 95 %, 1.04 to 6.50).
Conclusions: Although an observational study does not allow one to determine the casual relation between
frailty and endothelial dysfunction, we conclude that frailty was predominant in our sample of Brazilian patients
with chronic kidney disease on predialysis, even in elderly individuals. This was linked to either worse endothelial
function or mortality.
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Background
Frailty is a multidimensional syndrome that features a loss
of physiological reserves and is commonly related to ad-
vanced age, conferring a state of vulnerability among eld-
erly people [1]. Frailty is manifested through a loss of both
weight and strength, as well as exhaustion and low cap-
acity to exercise, and thereby places the afflicted individual
at increased risk of falls, hospitalization and death [2].
Patients with chronic kidney disease (CKD) are more
susceptible to frailty, probably owing to anemia, in-
flammation, dyslipidemia, and osteoarticular alterations
such as bone and mineral disorders and muscle dys-
function. In addition, CKD patients frequently present
with cardiovascular comorbidities, mainly secondary to
endothelial dysfunction, which clinically present as left
ventricular hypertrophy and reduced coronary perfu-
sion pressure [3].
Frailty has been studied in patients with CKD, mainly
those undergoing dialysis [4, 5], with a few publications
concerning predialysis patients [4, 6, 7]. In the only prior
study carried out in Brazil, we showed that frailty is
prevalent among predialysis patients, and is found even
among non-elderly individuals [8]. However, the rela-
tionship between frailty and endothelial dysfunction re-
mains unknown, even among individuals with CKD.
The goals of the present study are to evaluate the rela-
tionship between frailty and endothelial dysfunction in
Brazilian predialysis patients with CKD, and to evaluate
the impact of frailty on all-cause mortality and the need
for renal replacement therapy (RRT).
Methods
Study population
This study was approved by the Ethics Committee on
Research of the Federal University of Juiz de Fora and
informed consent was obtained from all patients prior to
enrollment in the study. The procedures were in accord-
ance with the ethical standards of the responsible com-
mittee on human experimentation and with the Helsinki
Declaration.
The patients, sampled by convenience, were recruited
from the CKD outpatient clinic of the IMEPEN Fouda-
tion of the Federal University of Juiz de Fora, Brazil. All
patients were diagnosed with CKD stages 3–5 and were
on predialysis. The diagnosis and categorization of CKD
was established according to the new CKD guidelines
[9]. The glomerular filtration rate (GFR) was estimated
from the serum creatinine level using the equation pro-
posed by the Modification of Diet in Renal Disease
Study [10].
Individuals were excluded from the study if they pre-
sented with severe neuropathy, gout, amputation, se-
vere physical sequelae caused by stroke, deep vascular
thrombosis, Parkinson’s, pregnancy, chronic pulmonary
obstruction disease, neoplasia, human immunodeficiency
virus infection, or cognitive impairment as determined by
the Mini Exam Mental State [11].
Between June 2011 and September 2012, 380 patients
were seen in the CKD clinic and 97 were considered
eligible for this study. However, 17 of these patients did
not agree to participate in the research, 9 had already
started dialysis, 8 died, and 2 could not be located,
amounting to a total of 61 patients who were included
in the study. At the 12-month follow-up, 1 patient
withdrew his consent, another patient moved to an-
other city, and 2 patients could not be located, totaling
to 57 patients being included for the follow-up analysis
(Fig. 1).
Assessment of frailty
To evaluate frailty, we used the criteria proposed by
Johansen et al. [5] It is a criteria similar or identical to
the modification by Woods et al. [12] of Fried’s criteria
for frailty2.
Scores were assigned for each criterion as follows:
muscle weakness (a score of 75 points on the Physical
Function scale of the Medical Outcomes Study 36 –
Item Short, 2 points; exhaustion (a score of 55 on the
Vitality scale of the SF-36), physical inactivity (patients
who reported that they “almost never or never” exer-
cised were classified as inactive), and unintentional
weight loss (ascertained using information available in
the medical chart within 30 day before study entry), 1
point each; this could total to a maximum of 5 points.
Frailty was diagnosed when patients were assigned ≥3
points.
We have chosen the Johansen’s criteria because it has
already been used in CKD patients and it uses direct
questions and issues presented in the SF-36, a question-
naire validated in the Brazilian population.
Measurement of other variables
Data on the etiology of CKD and the medications pre-
scribed were obtained from the medical records. The
body mass index (BMI) was assessed by dividing the
weight in kilograms by the height in meters squared.
Body composition and bone health were assessed using
dual-energy X-ray absorptiometry (DXA) of the whole
body, and the data generated were analyzed using
LUNAR EXPERT software, version 8.2 (GE LUNAR).
Abdominal circumference was measured as proposed in
the Third Report of the Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III) [13].
Laboratory tests were performed on blood samples
collected after 12 h of fasting. Part of the sample was
stored at −80 °C for assessment of tumor necrosis
factor-α (TNF-α; DuoSet R&D Systems, Minneapolis,
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MN, EUA) and interleukin-6 (R&D Systems, Minneap-
olis, MN, USA) levels following the protocols suggested
by the suppliers.
The 25-hydroxyvitamin D (25-OH-D) level in the
serum was determined using a high-performance liquid
chromatography method [14], and was considered ad-
equate at levels above 30 ng/mL.
Endothelial function
Endothelial function was assessed by an observer blinded
to the patient’s clinical status, using a Philips Envisor
ultrasound system, equipped with a high-frequency probe
(7–12 MHz.) and specific software for cardiac and vascu-
lar analysis. Fasting individuals were examined in the
morning; caffeine consumption and smoking were not
recommended on the day of the exams. Among female
patients, no evaluation was performed during the men-
strual cycle to avoid possible estrogen influence on endo-
thelial behavior.
The patients were requested to maintain an idle pos-
ition for at least 10 min in a temperature-controlled
room. Electrocardiographic monitoring was carried out
on channel 1 (CM5). The brachial artery was insonated
in a longitudinal plane in the antecubital fossa. The cuff
of a blood pressure monitor was placed on the arm.
Anatomical markers were used for proper positioning of
the transducer in order to obtain electrocardiographic
measurements from the brachial artery using R wave
amplitudes. Doppler ultrasound was also performed.
After assessing the basal images, bi-dimensional and
Doppler, the cuff was inflated to suprasystolic pressure
(50 mmHg above systolic pressure) for 5 min. The cuff
was then released quickly and either the bi-dimensional
images or Doppler evaluation of the brachial artery was
recorded for 5 min.
Flow-mediated vasodilatation (FMD) was assessed
using the maximum diameter of the artery obtained as a
percentage of the baseline. Reactive hyperemia was cal-
culated using the flow change as a percentage of the
baseline.
Values of less than 10 % of the variability found among
5 measures of pre- and post-pressure hyperemia were
adopted as the cutoff for normal FMD.
Follow-up
After 12 months, the patients or their relatives were
contacted by telephone and were questioned about
hospitalization history, need for RRT, and death. Need
for RRT or death was classified as the combined variable
outcome. Patients who survived and were not on dialysis
or did not receive any transplants were re-characterized
for frailty (Fig. 2).
Statistical analysis
For statistical analysis, STATA 11.0 ( STATACorp LP.
College Station, Texas) software was used. Descriptive
statistics for the mean with the standard deviation or the
median with the interquartile interval were applied as
necessary.
After using the Kolmogorov-Smirnov normality test,
the differences between the frail and non-frail groups
were evaluated. The student’s t-test was used for inde-
pendent groups when the normality test was not rejected;
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Fig. 1 Fluxogram of the sampling selection process used in the study
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The chi-squared test was used for analysis of categorical
variables.
The correlation between the obtained scores of frailty,
which used an ordinal scale of 6 points (0–5 points), and
the variables of the study was assessed using the Spear-
man correlation. The variable frailty, which is dichotom-
ous, was further analyzed by simple/bivariate logistic
regression models. For the multivariate model, all the
explicative variables that presented a chance of statistical
significance less than 20 % were excluded, but those pre-
senting significant statistical differences (p < 0,05) were
included in the model.
Survival analysis was used to assess outcomes and it
included the number of months reported by the indi-
viduals since the first appointment. In case of a lack of
outcome, 12 months was used as a temporary horizon,
and the observed data was censured. To verify the dif-
ference among the distribution of survival function, the
Kaplan–Meier approach with log-rank tests was used.
The hazard ratio was estimated by Cox regression
models adjusted according to gender and age.
Results
Characteristics of the cohort
At baseline, the average age of the patients was 60 ±
11.5 years; 41 % were women, 54.1 % were non-Caucasian,
27.9 % obese, and 14.8 % smokers. Hypertension was
found to be the main cause of CKD (29 %) and the main
associated comorbidity (57.4 %). The average serum cre-
atinine level was 2.3 (1.7–3.5) mg/dL and the average esti-
mated GFR was 23 (16.0–39.0) mL/min/1,73 m2 (Table 1).
Prevalence and characteristics of frail patients
The prevalence of frailty in the study group was 42.6 and
46 % of these cases occurred among non-elderly patients.
Compared to the non-frail group, the frail group mainly
comprised women and patients of a higher average age.
The frail group also comprised a higher number of Cauca-
sian subjects, although there was no statistically significant
difference when the 2 groups were compared. The preva-
lence of tobacco use too did not differ between the groups.
There was no difference between the estimated GFR
and number of patients per category of CKD when the
frail and non-frail groups were compared.
The analysis of body composition showed that the
BMI was similar in both groups, that there was no dif-
ference in the abdominal circumference between the
groups, and that frail patients presented with an in-
creased amount of fat mass, but not fat-free mass. Fur-
ther, the incidence of osteoporosis in the frail group was
100 %, compared to the 15.3 % in the non-frail group.
Hypertension and diabetes were the main causes of
CKD in frail patients. The occurrence of hypertension
(69.2 %), although high, was not different between the 2
groups. We observed higher values for serum intact
parathyroid hormone (iPTH) and transferrin saturation
index (TSAT) in the frail patients, but no significant dif-
ference was observed for thyroid-stimulating hormone,
total cholesterol, ferritin, hemoglobin, 25(OH)D, cal-
cium, phosphorus, bicarbonate, albumin, ultra-sensitive
C-reactive protein (CRP-us), interleukin-6 (IL-6), or
TNF-α between the groups.
Correlation between frailty and laboratory and clinical
data
Among the laboratory and clinical measurements, only fat
mass (r = 0.25; p = 0.05), endothelial function (r = −0.367;
p = 0.004), iPTH (r = 0.30; p = 0.01) TSAT (r = 0.1475; p =
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Fig. 2 Kaplan–Meier survival estimates between frail and non-frail subjects
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Association between frailty, FMD and others variables
The frail group had 9 subjects with FMD ≥ 10 % (34.6 %)
and the non frail had 21 subjects with FMD ≥ 10 %
(60 %).
In the bivariate analysis, the variables found to be as-
sociated with frailty were: female gender (odds ratio
[OR] = 3.41; 95 % confidence interval [CI] = 1.17–9.93),
age over 60 years (OR = 3.00; 95 % CI = 1.03–8.73), and
Table 1 Descriptive analysis of demographic, laboratorial and clinical data
Total (n = 61) Non-frail (n = 35) Frail (n = 26) P value
Age (years) 60.5 ± 11.5 57.3 ± 11.4 64.9 ± 10.3 0.009*
Female - n (%) 25 (41.0 %) 10 (28.6 %) 15 (57.7 %) 0.02*
Non-Caucasian - n (%) 33 (54.1 %) 22 (62.9 %) 11 (42.3 %) 0.11
Smoking - n (%) 9 (14.8 %) 5 (14.3 %) 4 (15.4 %) 0.90
BMI classification - n (%) 0.362
Malnourished ( <18,4 kg/m2) 2 (3.3 %) 1 (2.9 %) 1 (3.8 %)
Eutrophic (18,5 a 24,9 kg/m2) 20 (32.8 %) 14 (40 %) 6 (23.1 %)
Overweight (25,0 a 29,9 kg/m2) 22 (36.1 %) 13 (37.1 %) 9 (34.6 %)
Obese ( ≥30,0 kg/m2) 17 (27.9 %) 7 (20 %) 10 (38.5 %)
Fat mass (kg) – mean (SD) 22.1 ± 8.2 20.3 ± 7.4 24.6 ± 8.7 0.05*
Fat-free mass (kg) – mean (SD) 46.6 ± 11.3 48.5 ± 9.7 44.1 ± 12.9 0.148
Abdominal circumference – mean (SD) 94.14 ± 13.6 91.6 ± 13.0 97.4 ± 13.9 0.107
Comorbidities – n (%) 0.235
Hypertension 35 (57.4 %) 17 (48.6 %) 18 (69.2 %)
Diabetes Mellitus 1 (1.6 %) 1 (2.9 %) 0 (0 %)
Hypertension and Diabetes Mellitus 11 (18 %) 6 (17.1 %) 5 (19.2 %)
Not present 14 (23 %) 11 (31.4 %) 3 (11.5 %)
Osteopenia/Osteoporosis – n (%) 0.01*
Osteopenia 12 (19.7 %) 8 (22.9 %) 4 (15.4 %)
Osteoporosis 6 (9.8 %) 0 (0 %) 6 (23.1 %)
Creatinine (mg/dL) a 2.3 (1.7–3.5) 2.2 (1.6–3.4) 2.4 (1.8–3.6) 0.53
GFR (mL/min/1,73 m2) a 23 (16.0–39.0) 28 (18.0–41.0) 22 (14.7–32.2) 0.15
Glicemia (mg/dL) a 91 (83.5–102.5) 92 (86.0–100.0) 88.5 (79.5–104.2) 0.79
iPTH (pg/ml) a 149.3 (95.4–358.5) 127.9 (84.1–264.1) 248.8 (124.3–409.7) 0.02*
TSH (μUI/mL) a 2.2 (1.4–3.1) 2.4 (1.4–3.3) 2.0 (1.3–2.7) 0.70
Total cholesterol (mg/dL) – mean (SD) 178.0 ± 38.4 177.1 ± 36.9 179.3 ± 41.0 0.83
Ferritin (ng/dL) a 126.4 (79.1–202.6) 103.6 (71.3–209.9) 128.4 (89.1–202.2) 0.47
TSAT (%) – mean (SD) 34.1 ± 12.5 37.1 ± 12.9 30.1 ± 11.1 0.02*
Hemoglobin (g/dL) – mean (SD) 12.9 ± 1.7 13.3 ± 1.8 12.4 ± 1.6 0.07
TNF-α (pg/ml) a 9.7 (5.6–29.5) 10.0 (6.5–35.8) 8.6 (5.5–16.2) 0.27
IL-6 (pg/ml) a 2.7 (1.9–4.5) 2.3 (1.8–4.1) 3.2 (1.9–4.6) 0.22
CRP (mg/L) a 2.1 (1.3–4.1) 1.7 (1.1–4.2) 2.4 (1.5–4.1) 0.28
Vitamin D (nmol/L) – mean (SD) 21.9 ± 3.8 22.1 ± 3.6 21.5 ± 4.1 0.52
Calcium (mg/dL) – mean (SD) 9.8 ± 1.1 9.8 ± 0.9 9.8 ± 1.4 0.79
Phosphorus (mg/dL) – mean (SD) 3.8 ± 0.9 3.8 ± 0.8 3.8 ± 1.0 0.95
Calcium x phosphorus product (mg/dL) – mean (SD) 37.2 ± 9.0 36.4 ± 8.7 38.2 ± 9.4 0.45
aNon-normal variable: data presented as median (Interquartil Interval)
- Normal variable: mean ± standard deviation
*p < 0,05
FMD flow-mediated vasodilatation, ESA eritropoiesis-stimulating agent, GFR glomerular filtration rate, iPTH Intact parathyroid hormone, TSH Thyroid-stimulating
hormone, TSAT Transferrin saturation index, TNF-α Tumor necrosis factor-alfa, IL-6 Interleucin 6, CRP C-reactive protein (ultrasensitive) test
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endothelial dysfunction (OR = 2.83; 95 % CI = 0.99–8.13)
(Table 2).
After adjusting for confounding variables, frailty was
found to be associated with gender (OR = 11.32; 95 % CI
= 2.30–55.67), advanced age (OR = 4.07; 95 % CI = 1.02–
16.20), and obesity (OR = 6.63; 95 % CI = 0.82–11.44)
(Table 3). The values for CRP-us and 25-OH-D are not
described here because those patients with inadequate
levels were all included in the frail group. Frailty was also
associated with endothelial dysfunction (OR = 3.86; 95 %
CI = 1.00–14.88).
Association between frailty and negative outcomes
Re-evaluation of the patients at the 12-month follow-
up, after adjusting for age and gender, revealed that
frailty accounted for a hazard ratio of 2.5 (95 % CI =
1.04–6.10), a greater risk of negative health outcomes.
When evaluating the survival curves comparing the
groups generated by the combination of frailty and FMD,
the log rank test gives a p-value of 0.09. Although
insufficient to reject the null hypothesis of homogeneity of
the survival curves between the groups, draws attention
that under the assumption of the same null hypothesis,
the expected negative outcomes in the stratum formed by
frailty and FMD <10 % value would be 5 events (provided
by the estimates used in the log-rank test). However, we
observe 10 events, twice the expected, what make us sup-
pose about an interactive detrimental effect of frailty and
FMD to explain the increased risks of outcomes observed,
which did not reach a p-value <0.05 probably due to the
small sample size.
Discussion
Using a study cohort comprising Brazilian predialysis
patients, we observed that frailty occurs at a high fre-
quency; is prevalent even among non-elderly patients; is
associated with gender, advanced age, obesity, and endo-
thelial dysfunction; and that it identifies individuals with
a higher chance of unfavorable outcomes, including need
for RRT, hospitalization, or death.
Barreto [15] argued for the universality of evaluating
frailty in any culture or country. The author justifies his
conclusion on the basis of the fact that the causes of
frailty are linked to biological deficits, most of which are
due to advanced age, and therefore reflects the quantifi-
cation of health vulnerability. On the other hand, such
vulnerability may vary depending on genetic, behavioral,
or social characteristics, supporting the idea of having a
specific evaluation to assess frailty according to coun-
tries or regions. Moreover, even though frailty usually
assesses such criteria, it also follows social, environmen-
tal, and psychological trends, emphasizing the necessity
of evaluating frailty using customized instruments for a
specific culture or local areas.
The comparison of studies on the prevalence of frailty is
hindered by the innumerous diagnostic models of frailty as
well as the different locations where the evaluations took
place. Santos-Eggimann et al. [16] compared frailty preva-
lence in 10 European countries and found prevalences that
varied from 3.9 to 21 %. In another multicenter study in-
volving 5 countries in South America, Alvarado et al. [17]
Table 2 Analysis of raw odds ratio
Variables OR P value IC 95 %
Female 3.41 0.03 1.17 9.93
>60 years 3.00 0.04 1.03 8.73
Overweight (BMI: 25 – 29.9 kg/m2) 1.48 0.53 0.43 5.10
Obese (BMI≥ 30 kg/m2) 3.06 0.10 0.82 11.44
Abdominal circunference
(H≥ 94 cm; M ≥ 80 cm)
2.48 0.14 0.75 8.18
Anemia (Hb ≤ 11 g/dL) 1.39 0.71 0.25 7.52
Glycemia (100 mg/dL) 1.81 0.29 0.60 5.40
Phosphorusa 0.24 0.21 0.02 2.19
Calcium (8,4 a 9,5 mg/dL) 0.77 0.63 0.28 2.17
iPTHb 1.62 0.47 0.43 6.14
TSH (4,0 μUI/mL) 2.00 0.43 0.36 11.23
Serum albumin (3,5 mg/dL) 2.00 0.19 0.70 5.69
Total cholesterol (200 mg/dL) 1.28 0.66 0.42 3.96
LDL-c (130 mg/dL) 1.09 0.91 0.26 4.54
HDL-c (H≥ 60 mg/dL; M≥ 50 mg/dL) 0.64 0.42 0.22 1.88
TGL (150 g/dL) 0.79 0.67 0.28 2.28
TSAT (≥20 %) 0.51 0.41 0.10 2.53
Ferritin (≤100 ng/dL) 0.62 0.38 0.22 1.79
HCO3 (22 mmol/L) 1.02 0.97 0.37 2.85
FMD (dif ≥10 %) 2.83 0.05 0.99 8.13
TNF-α (pg/ml) c 1.16 0.79 0.39 3.39
IL-6 (pg/ml) d 1.25 0.49 0.66 2.35
aP (Stages 3 and 4: 2.7 to 4.6 mg/dL, Stage 5: 3.5 to 5.5 mg/dL)
biPTH (Stage 3: 35 a 70 pg/ml, Stage 4: 70 a 110 pg/ml, Stage 5: 110 to
300 pg/ml)
cTNF-α (<6.83 pg/ml; 6.83–19.22 pg/ml; >19.22 pg/ml)
dIL-6 (<2.13 pg/ml; 2.13–3.9 pg/ml; >3.9 pg/ml)
FMD flow-mediated vasodilatation
Table 3 Multivariated regression analysis
Variable OR P > z IC 95 %
Female 11.32 0.00 2.30 55.67
Age > 60 years 4.07 0,05 1.02 16.20
Eutrophic 1 ——— ——— ———
Overweight 3.05 0.17 0.63 14.68
Obese 6.63 0.03 1.19 36.77
FMD 3.86 0.05 1.00 14.88
FMD flow-mediated vasodilatation
Variable used in multivariated regression: Anemia, waist circumference,
glycemia, TSH, IL-6, PCR
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found prevalences of frailty that varied from 27 to 40 % in
both genders. In Alvarado’s study, although the instrument
employed was different from the instrument that we used,
the authors described a prevalence of 40.6 % among
Brazilian participants, similar to that identified among
our patients (42.6 %).
Irrespective of the instrument chosen for assessing
frailty, the majority of studies linking frailty to CKD shows
an association between frailty, advanced age [4, 5], and fe-
male gender [4]. Our data show that 46 % of the frail
population was less than 60 years old, a finding in agree-
ment with the data obtained in another study performed
by our group, which included patients undergoing dialysis.
These findings are similar to those described in American
patients on dialysis, where the same instrument was used
for assessment of frailty [5].
More recently, Roshanravan et al. [7] used the criteria
of frailty described by Fried et al. [2] and found compar-
able results in predialysis patients in the USA. Taken to-
gether, these data point towards a possible association of
frailty with inflammation and endothelial dysfunction,
both also common in patients with CKD.
Although weight loss is one of the components of
frailty, it was found in only 4 (11.5 %) of our patients;
the frail group presented an average serum albumin level
of 3.5 ± 0.3 g/dL. Multivariate analysis identified a strong
association between obesity (assessed by DXA) and
frailty. Together, these findings suggest that frailty, in this
group of patients, was not due to undernourishment.
Excess weight can be associated with some of the cri-
teria used and with the risk factors typically associated
with frailty. Obese patients demonstrate impaired phys-
ical function and become exhausted more easily [18, 19].
Additionally, obesity can prompt a pro-inflammatory
condition, common in frail individuals [20, 21]. The dir-
ect relationship between frailty and obesity was found
by Fried et al. [21] in frail older women, who presented
more subcutaneous fat, as assessed through skin fold
tests. Similarly, Sanders et al. [22] have also reported an
association between excess weight, assessed through
BMI, and frailty, assessed by a 10-point scale of frailty.
On the other hand, Alvarado et al. [17] did not find any
association between high BMI and frailty in a Latin–
American elderly population. We also did not find any
association between frailty and BMI, although compared
to the non-frail group, the frail group comprised less
eutrophic (23.1 × 40 %) and more obese (38.5 × 20 %)
patients.
Nevertheless, Hubbard et al. [23] noticed a relation-
ship between BMI and frailty when the subject was
undernourished or overweight and obese, especially in
those presenting larger abdominal circumference. In our
study, the abdominal circumference was not statistically
different among the groups, but it is likely that there is a
clinical difference among them (frail = 97.4 ± 13.9 cm;
non-frail = 91.6 ± 13.0 cm).
In our study, there was no statistical difference be-
tween frail and non-frail patients regarding muscle mass,
possibly due to the absence of metabolic acidosis and a
good nutritional state.
Notably, osteoporosis was documented (23 %) only in
patients with frailty, since we have found no prior stud-
ies associating frailty with bone mineral disorders in
patients with CKD.
One of the factors that can explain such relationships is
the secondary hyperthyroidism that was more frequently
observed in the frail group, which was also correlated to
the criteria of frailty, although it lost statistical strength
following adjustments. The other variables associated with
bone and mineral metabolism (calcium, phosphorus, and
vitamin D), and were different between the groups, al-
though not significant, were shown to be protective factors
according to the bivariate analysis. It is also worth noting
that glucocorticoid and vitamin D use was not different
between the groups, and they probably did not influence
the relationship between frailty and bone metabolism.
Vitamin D has been associated with frailty in many
studies on elderly populations [24–26]. Nonetheless, in
our study, there was no association between frailty and
vitamin D, probably due to the fact that both groups
presented vitamin D insufficiency, even though the pa-
tients resided in a sunny country. Our findings are in ac-
cordance with studies reported by Cuppari et al. [27]
and Diniz et al. [28], who also observed lower levels of
vitamin D in the Brazilian population with CKD.
Perhaps the most relevant result identified here was
the strong association of endothelial dysfunction with
frailty that, to the best of our knowledge, has not been
reported in the literature.
The association between endothelial function and
frailty might be due to the sympathetic hyper-activation
of CKD [29], generating an autonomous dysfunction
and, consequently, a reduction of vascular perfusion in
the skeletal muscle. However, the evaluation of sympa-
thetic activity was not an objective of the current study.
Another hypothesis for the association between frailty
and endothelial dysfunction is oxidative stress, which is re-
lated to endothelial dysfunction in patients with CKD [30].
According to an animal study, the increase in oxidative
stress, coupled with the reduction in nitric oxide produc-
tion, may generate a reduction in nitric oxide bioavailabil-
ity, thereby inducing endothelial dysfunction [31].
In our study, only 34.6 % of the patients presented
with FMD greater than 10 % of the difference between
the evaluation of pre- and post-hyperemia, while in the
non-frail group, 60 % of the patients presented such
values. When correlating endothelial function with the
scores of frailty criteria, we found a strong negative
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association. Moreover, the risk of being frail when the
FMD was less than 10 % was 2.83 according to bivariate
regression analysis and 3.86 according to multivariate re-
gression analysis.
In contrast to the majority of the studies that assessed
the relationship between frailty and inflammatory markers,
our results obtained using CRP-us, IL-6, and TNF-α did
not demonstrate any such relationship, which could be
due to the great variability observed in the results of these
markers, reinforcing the existence of another association
between endothelial function and frailty.
Because we have identified a strong association between
endothelial function and frailty, and because we did not
identify the same trend for inflammatory markers, we sug-
gest another hypothesis that can explain the relationship
between frailty and endothelial function: vascular calcifica-
tion of the tunica media, common in patients with CKD
[32], which is likely to produce a reduction in vascular
perfusion. Despite the normal values of calcium and phos-
phorus reported in our study population, this hypothesis
can be justified by the presence of hyperparathyroidism or
even by the presence of free radicals, which is common to
the referred population, although it was not assessed in
our study.
The relationship between physical capacity and negative
health outcomes in CKD remains unknown [33]. In terms
of frailty, its relationship with negative outcomes is posi-
tive and well documented in the literature [2, 34–37].
However, few studies demonstrate the relationship be-
tween frailty and negative health outcomes in the CKD
population [5–7, 38]. Among them, only 2 were con-
ducted on non-dialysis patients [6, 7], but using only 1
creatinine estimation [7].
All the results describing frailty in patients with CKD,
apart from the criteria of frailty used, acknowledge our
results. Our data show that the negative outcomes were
more common in frail patients (HR = 2.51; 95 % CI =
1.04–6.10). Wilhelm-Leen et al. [6] reported an HR of
2.21 (95 % CI = 1.49–3.28) for patients in stages 1 and 2
between frailty and mortality, 2.48 for patients in stage
3A (95 % CI = 1.57–3.93), and 5.58 for patients between
stages 3B and 5 (95 % CI = 3.40–10.16). Bao et al. [39]
and Johansen et al. [5] studied the same relationship
between mortality and frailty in dialysis patients and
found an HR of 1.75 (95 % CI = 1.44–2.24) and 2.24
(95 % CI = 1.60–3.15), respectively.
However, our study has some limitations. This was a
single-centered study, and hence, comprised a small
study sample. Further, the observational nature of this
study did not allow for the identification of a causal rela-
tionship. Despite the use of known criteria to assess
frailty, we consider the evaluation of physical activity less
useful in determining the fenotype of frailty, although a
high index of sedentary behavior was found.
Conclusion
In conclusion, we documented an elevated frailty preva-
lence in a sample of Brazilian predialysis patients. We
found frailty to be associated with gender (female), age
over 60 years-old), obesity, and endothelial dysfunction.
In addition, we found a high percentage of non-elderly
patients with frailty. Nevertheless, prospective and ran-
domized studies are necessary to investigate the cause-
and-effect relationship between frailty and endothelial
function, perhaps by assessing oxidative stress.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HNM was responsable for the elaboration, execution and article writing.
JCML and NRBR participated as colaborattors for the elaboration, execution
and article writing. FABC and NMSF were responsible for the elaboration,
statistical analysis and critical review of the study. MGB was responsable for
the elaboration, statistical treatment and critical review of the study. All
authors read and approved the final manuscript.
Author details
1IMEPEN Foundation, Federal University of Juiz de Fora, Juiz de Fora, Brazil.
2Academic Centre of Vitoria, Federal University of Pernambuco, Vitória de
Santo Antão, Pernambuco, Brazil. 3Federal University of Juiz de Fora, José
Lourenço Kelmer Street, 1300, Juiz de Fora, Minas Gerais, Brazil.
Received: 5 April 2014 Accepted: 11 September 2015
References
1. Rockwood K, Song X, Macknight C, Bergman H, Hogan DB, McDowell I, et al.
A global clinical measure of fitness and frailty in elderly people. CMAJ.
2005;173(5):489–95.
2. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al.
Collaborative Research Group for the Cardiovascular Health Study: Frailty in
older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci.
2006;56A(3):M146–56.
3. Kosch M, Levers A, Barenbrock M, Matzkies F, Schaefer RM, Kisters K, et al.
Accute effects of haemodialysis on endothelial function and large artery
elasticity. Nephrol Dial Transplant. 2001;16(8):1663–68.
4. Shlipak MG, Stehman-Breen C, Fried LF, Song X, Siscovick D, Fried LP, et al. The
presence of frailty in elderly persons with chronic renal insufficiency. Am J
Kidney Dis. 2004;43(5):861–7.
5. Johansen LK, Chertow GM, Jin C, Kutner NG. Significance of frailty among
dialysis patients. J Am Soc Nephrol. 2007;18(11):2960–7.
6. Wilhelm-Leen ER, Hall YN, Tamura MK, Chertow GM. Frailty and chronic
kidney disease: the Third National Health and Nutrition Evaluation Survey.
Am J Med. 2009;122(7):664–71.
7. Roshanravan B, Khatri M, Robinson-Cohen C, Levin G, Patel KV, de Boer IH,
et al. A prospective study of frailty in nephrology-referred patients with
CKD. Am J Kidney Dis. 2012;60(6):912–21.
8. Mansur HN, Damasceno VO, Bastos MG. Prevalence of frailty in patients with
chronic kidney disease not yet and on dialysis. Braz J Nephrol.
2012;34(2):153–60.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic
kidney disease: evaluation, classification and stratification. Am J Kidney Dis.
2002;39 Suppl 2:S1–S246.
10. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate
accurate method to estimate glomerular filtration rate from serum
creatinine: a new prediction equation. Modification of Diet in Renal Disease
Study Group. Ann Intern Med. 1999;130(6):461–70.
11. Brucki SM, Nitrini R, Caramelli P, Bertolucci PH, Okamoto IH. Suggestions for
utilization of the mini-mental state examination in Brazil. Arq
Neuropsiquiatr. 2003;61(3B):777–81.
Mansur et al. BMC Nephrology  (2015) 16:157 Page 8 of 9
12. Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, et al. Frailty:
emergence and consequences in women aged 65 and older in the Women’s
Health Initiative Observational Study. J Am Geriatr Soc. 2005;53:1321–30.
13. The Third Report of the National Cholesterol Education Program (NECP). Expert
Panel on Detection. Evaluation, and treatment of high blood cholesterol in
adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.
14. Melhus H, Snellman G, Gedeborg R, Byberg L, Berglund L, Mallmin H, et al.
Plasma 25-hydroxyvitamin D levels and fracture risk in a community-based
group of elderly men in Sweden. J Clin Endocrinol Metab. 2010;95(6):2637–45.
15. Barreto PS. One operational definition by population: the need for local
evaluation of frailty. J Physiol Anthropol. 2011;30(6):259–62.
16. Santos-Eggimann B, Cuénoud P, Spagnoli J, Junod J. Prevalence of frailty in
middle-aged and older community-dwelling Europeans living in 10 countries.
Gerontol A Biol Sci Med Sci. 2009;64(6):675–81.
17. Alvarado BE, Zunzunnegui V, Beland F, Bamvita J. Life course social and
health conditions linked to frailty in Latin American older men and women.
J Gerontol. 2008;63A(12):1399–406.
18. Bautmans I, Gorus E, Njemini R, Mets T. Handgrip performance in relation to
self-perceived fatigue, physical functioning and circulating IL-6 in elderly
persons without inflammation. BMC Geriatrics. 2007;7:5.
19. Leng S, Chaves P, Koenig K, Walston J. Serum interkeukin-6 and hemoglobin
as physiological correlates in the geriatric syndrome of frailty: a pilot study.
J Am Geriatr Soc. 2002;50(7):1268–71.
20. Chang SS, Weiss CO, Xue Q-I, Fried LP. Association between
inflammatory- related disease burden and frailty: results from the
Women’s Health and Aging Studies (WHAS) I and II. Arch Gerontol
Geriatr. 2012;54(1):9–15.
21. Fried LP, Xue Q-I, Cappola AR, Ferrucci L, Chaves P, Varadhan R, et al. Nonlinear
multisystem physiological dysregulation associated with frailty in older
women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci.
2009;64(10):1049–57.
22. Sanders JL, Boudreau RM, Fried LP, Walston JD, Harris TB, Newman AB.
Measurement of organ structure and function enhances understanding of
the physiological basis of frailty: the Cardiovascular Health Study. J Am
Geriatr Soc. 2011;59(9):1581–8.
23. Hubbard RE, Lang A, Lewellyn DJ, Rockwood K. Frailty, body mass index, and
abdominal obesity in older people. J Gerontol A Biol Sci Med Sci.
2010;65(4):377–81.
24. Shardell M, Hicks GE, Miller RR, Kritchevsky S, Andersen D, Bandinelli S, et al.
Association of low vitamin D levels with the frailty syndrome in men and
women. J Gerontol A Biol Sci Med Sci. 2009;64(1):69–75.
25. Ensrud KE, Ewing SK, Fredman L, Hochberg MC, Cauley JA, Hillier TA, et al.
Circulating 25-hydroxyvitamin D levels and frailty status in older women.
J Clin Endocrinol Metab. 2010;95(12):5266–73.
26. Ensrud KE, Blackwell TL, Caulley JA, Cummings SR, Barrett-Connor E, Dam TL, et al.
Circulating 25-hydroxyvitamin D levels and frailty in older men: the osteoporotic
fractures in men study. J Am Geriatr Soc. 2010;59(1):101–6.
27. Cuppari L, Carvalho AB, Draibe AS. Vitamin D status of chronic kidney
disease patients living in a Sunny Country. J Ren Nutr. 2008;18(5):408–14.
28. Diniz HF, Romão MF, Elias RM, Romão Júnior JE. Vitamin D deficiency and
insufficiency in patients with chronic kidney disease. J Bras Nefrol.
2012;34(1):58–63.
29. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, et al. Early
sympathetic activation in the initial clinical stages of chronic renal failure.
Hypertension. 2011;57(4):846–51.
30. Martens CR, Edwards DG. Peripheral vascular dysfunction in chronic kidney
disease. Cardiol Res Pract. 2011;201:257–67.
31. Nakayama T, Sato W, Kosuqi T, Zhang L, Campbell-Thompson M, Yoshimura A,
et al. Endothelial injury due to eNOS deficiency accelerates the progression of
chronic renal disease in the mouse. Am J Physiol Renal Physiol.
2009;296(2):F317–327.
32. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney
disease. J Am Soc Nephrol. 2008;19(2):213–6.
33. Chen JLT, Lerner D, Ruthazer R, Castaneda-Sceppa C, Levey AS. Association of
physical activity with mortality in chronic kidney disease. J Nephrol.
2008;21(2):243–52.
34. Rockwood K, Song X, Mitnitski A. Changes in relative fitness and frailty across
the adult lifespan: evidence from the Canadian National Population Health
Survey. CMAJ. 2011;183(8):E487–94.
35. Shi J, Song X, Yu P, Tang Z, Mitnitski A, Fang X, et al. Analysis of frailty and
survival from late middle age in the Beijing Longitudinal Study of Aging.
BMC Geriatrics. 2011;11:17.
36. Fallah N, Mitnitski A, Searle SD, Gahbauer EA, Gill TM, Rockwood K. Transitions
in frailty status in older adults in relation to mobility: a multistate modeling
approach employing a deficit count. J Am Geriatr Soc. 2011;59(3):524–9.
37. Masel MC, Ostir GV, Ottenbache KJ. Frailty, mortality, and health related quality
of life in older Mexican Americans. J Am Geriatr Soc. 2010;58(11):2149–53.
38. García-González J-J, García-Peña C, Franco-Marina F. A frailty index to
predict the mortality risk in a population of senior Mexican adults. BMC
Geriatr. 2009;9:47.
39. Bao Y, Dalrymple L, Chertow GM, Kaysen GA, Johansen KL. Frailty, dialysis
initiation, and mortality in end-stage renal disease. Arch Intern Med.
2012;172(14):1071–7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mansur et al. BMC Nephrology  (2015) 16:157 Page 9 of 9
